Ethics Policy Announced for NIH Officials – LAT Tue, 2 Mar 2004 This is a case demonstrating the power of the press ( the “fourth estate”) in its most important role providing a check on the abuse of government power. An investigative report by David Willman, Pulitzer Prize winning journalist of the Los Angeles Times…

Read More

Double Dipping at NIH: “the Gaming Must End” – Editorial WashPost Tue, 6 Jul 2004 Monday’s Washington Post editorial took a critical of the corrupting influence of the pharmaceutical industry on scientists at the National Institutes of Health. The agency’s “lax ethics rules, laxly enforced” has resulted in scientists “[pocketing] fat consulting fees, at times…

Read More

NIH Expert on Safe Drug Research Seeks Whistleblower Protection Tue, 14 Dec 2004 In the wake of the Associated Press investigative report about unethical NIH-sponsored AIDS research involving infants and pregranant women Africa, and charges of misconduct by high officials at the National Institutes of Health (NIH), Senate Finance Committee Chairman Charles E. Grassley has…

Read More

Stealth Merger: Drug Companies and Medical Research at NIH – LAT Sun, 7 Dec 2003 Los Angeles Times reporter, David Willman, who twice won the Pulitzer Prize (1994, 2001) has once again demonstrated what fine investigative journalism is about. His investigative series in 2000 put the spotlight on conflicts of interest at the FDA, and…

Read More

Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine

The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval.

Read More

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which…

Read More

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav March 8, 2002  FDA and Pharmaceutical Industry inPrivate Deal to Speed Drug Approval Process FYI According to the Washington Post, the FDA hasreached an agreement with the pharmaceutical industry to further speed…

Read More

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav February 19, 2002 How a New FDA Policy Led toSeven Deadly Drugs FYI The Seattle Times reports, "Therelationship between the FDA and pharmaceutical industry changed fundamentallyunder former President Clinton, and the agency was…

Read More

 Medicine: Once a wary watchdog, the Food and Drug Administration set out to become a "partner" of the pharmaceutical industry. Today, the public has more remedies, but some are proving lethal.

Read More